see the effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY study - https://t.co/AannKA17OJ
"We do much more complicated things, we use much more dangerous drugs for other conditions that don't deliver like this"
"And if you don't do it, you're likely to become obsolete... because someone else will"
Professor Tuttle with a #kidneywk call to arms 🔥🔥🔥 #kidneycompass
No effects of probiotics and fibers on markers of nephropathy, inflammation and intestinal barrier in T1D during a 12w study
https://t.co/kQaMTLQeZ2 @Stenodiabetes@buur_stougaard
Severely increased albuminuria at screening is a powerful criterion for selecting persons with T1D at high risk of kidney function decline.
https://t.co/7Z8TbzQapJ
Our latest NUDGE trial just published in @JAMA_current 👇
Led by the brilliant @niklasdj1, in collaboration with amazing colleagues from @SSI_dk@harvardmed@Region_Midt and many more.
@CTCPR_ continues to provide important evidence regarding how we can improve public health
Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial | @NatureMedicine Spiro was often discontinued and no effect on outcome https://t.co/uUAa0mfHTj
The first simpub from the @CTCPR_ team during #ESC2024. The NUDGE-FLU-2 trial results in @NatureMedicine lead by @niklasdj1 👇
Electronic nudges for sustained influenza vaccination uptake in older adults (>65): the nationwide randomized NUDGE-FLU-2 trial
https://t.co/qgIQ2G6Q4T
Bnefit of semaglutide in heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
https://t.co/dKRSKWGfjF